Tutto DSpace

Sfoglia per Soggetto "infliximab"

Items 21-25 di 25

    • The risk of lymphoma development in autoimmune diseases: A meta-analysis 

      Zintzaras, E.; Voulgarelis, M.; Moutsopoulos, H. M. (2005)
      Background: The risk of development of non-Hodgkin lymphoma (NHL) in autoimmune patients has been investigated in several cohort studies. These studies revealed inconclusive results. To shed some light on this controversy, ...

    • Serum laminin and collagen IV in inflammatory bowel disease 

      Koutroubakis, I. E.; Petinaki, E.; Dimoulios, P.; Vardas, E.; Roussomoustakaki, M.; Maniatis, A. N.; Kouroumalis, E. A. (2003)
      Background/Aims: Laminin and collagen IV have been proposed as extracellular matrix serum markers. Because fibrosis is a major complication of inflammatory bowel disease, serum concentrations of laminin and collagen IV ...

    • Time to Deal with Rheumatoid Cachexia: Prevalence, Diagnostic Criteria, Treatment Effects and Evidence for Management 

      Efthymiou E., Grammatikopoulou M.G., Gkiouras K., Efthymiou G., Zafiriou E., Goulis D.G., Sakkas L.I., Bogdanos D.P. (2022)
      Cachexia is an early result of rheumatoid arthritis (RA) (rheumatoid cachexia, RC), characterised mainly by involuntary loss of fat-free mass. RC is apparent in 1-67% of patients with RA, depending on the diagnostic criteria ...

    • Use of TNFα antagonists in refractory AIH: Revealing the unforeseen 

      Saitis, A.; Gatselis, N.; Zachou, K.; Dalekos, G. N. (2013)

    • Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis 

      Lopez-Rodriguez R., Perez-Pampin E., Marquez A., Blanco F.J., Joven B., Carreira P., Ferrer M.A., Caliz R., Valor L., Narvaez J., Cañete J.D., Del Carmen Ordoñez M., Manrique-Arija S., Vasilopoulos Y., Balsa A., Pascual-Salcedo D., Moreno-Ramos M.J., Alegre-Sancho J.J., Navarro-Sarabia F., Moreira V., Garcia-Portales R., Raya E., Magro-Checa C., Martin J., Gomez-Reino J.J., Gonzalez A. (2018)
      Genetic biomarkers are sought to personalize treatment of patients with rheumatoid arthritis (RA), given their variable response to TNF inhibitors (TNFi). However, no genetic biomaker is yet sufficiently validated. Here, ...